TD Asset Management Inc Sells 13,830 Shares of Kestra Medical Technologies, Ltd. $KMTS

TD Asset Management Inc trimmed its stake in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 14.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 78,718 shares of the company’s stock after selling 13,830 shares during the period. TD Asset Management Inc owned approximately 0.15% of Kestra Medical Technologies worth $1,305,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of KMTS. Yu Fan bought a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $56,880,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $56,613,000. Omega Fund Management LLC bought a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $44,754,000. Alliancebernstein L.P. bought a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $29,500,000. Finally, Brown Advisory Inc. purchased a new position in Kestra Medical Technologies during the 1st quarter valued at $13,716,000.

Kestra Medical Technologies Stock Down 1.2%

Shares of NASDAQ KMTS opened at $26.07 on Thursday. The company has a quick ratio of 6.84, a current ratio of 6.84 and a debt-to-equity ratio of 0.23. The business has a fifty day simple moving average of $21.20 and a two-hundred day simple moving average of $20.19. Kestra Medical Technologies, Ltd. has a twelve month low of $13.25 and a twelve month high of $27.71.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Thursday, September 11th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.20. The firm had revenue of $19.37 million for the quarter, compared to the consensus estimate of $17.68 million. Kestra Medical Technologies has set its FY 2026 guidance at EPS.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on KMTS shares. Wells Fargo & Company dropped their price objective on Kestra Medical Technologies from $28.00 to $27.00 and set an “overweight” rating for the company in a report on Thursday, July 17th. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Kestra Medical Technologies in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $27.33.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.